ABCG2 and neoplasm: Interestingly, the cisplatin++ group mirrored the cisplatin+ group by exhibiting an increase in EpCAM+/ABCG2+/pimonidazole+ CTCs between the 2nd and 8th week of tumor growth (Figure 9D).